Key clinical point: Deferasirox plus deferoxamine is more effective than deferasirox alone for treating iron overload in patients with thalassemia major.
Major finding: Myocardial T2* decreased slightly in the monotherapy group (P = .3) but increased significantly in the combination group (P less than .05). There was no significant change in hepatic iron in either group.
Study details: A single-center, randomized study of 55 evaluable patients with thalassemia major.
Disclosures: The study was supported by Arak University of Medical Sciences, and the researchers reported having no conflicts of interest.
Eghbali A et al. Transfus Apher Sci. 2019 Aug;58(4):429-33.